Pirarubicin Hydrochloride (C09-1165-323)

Pirarubicin Hydrochloride is an anthracycline antibiotics , acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.In VitroPirarubicin 是一种拓扑异构酶 II 抑制剂。 Pirarubicin 对 M5076 和 Ehrlich 细胞具有抑制活性，IC 50 分别为 0.366 和 0.078 μM。Pirarubicin 对 M5076 细胞的细胞毒性低于对 Ehrlich 细胞的细胞毒性，这是由于 M5076 细胞中拓扑异构酶 II 的表达远低于 Ehrlich 细胞。 Pirarubicin (2.5，5，10 μg/mL) 在膀胱癌 (T24、EJ、5637、J82 和 UM-UC-3) 细胞中以剂量依赖性方式显著诱导自噬。此外，Pirarubicin (5 μg/mL) 通过抑制膀胱癌细胞中的 mTOR/p70S6K/4E-BP1 诱导细胞凋亡，这种作用因抑制自噬而增强。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.In Vivo在急性心脏毒性大鼠中，与对照组相比，Pirarubicin (18 mg/kg，iv) 显著提高 BNP、CK-MB、CTnT、LDH 和 MDA 的血清水平。在急性心脏毒性模型中，Pirarubicin Hydrochloride 还可以降低心率，降低 R 波电压，延长 QT 间期。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:Topoisomerase II. Specifications and Purity: 10mM in DMSO. Molecular Formula: C32H38ClNO12. Molecular Weight: 664.10.